Biosimilar Rheumatology Roundup: March 2022
March 31st 2022
By Skylar Jeremias
ArticleDuring the month of March, rheumatology biosimilars have received a lot of praise in a regulatory, business, and legal sense, especially regarding the landmark settlement between Alvotech and AbbVie over an adalimumab biosimilar.